Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BID | P55957 | 6/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7718333 | 0.98 | BID (0.49) | BIDMCL1BCL2L1BAK1PPARA | |
| Ammonia Solution, Strong SCHEMBL7718335 | 0.98 | BID (0.49) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL906286 | 0.95 | BID (0.57) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL27782113 | 0.95 | BID (0.57) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL28370702 | 0.95 | BID (0.56) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL15344563 | 0.95 | BID (0.45) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL4185670 | 0.93 | BID (0.59) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL29678096 | 0.93 | BID (0.59) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL8734778 | 0.93 | BID (0.59) | BIDMCL1BCL2L1BAK1PPARA | |
| SCHEMBL28593799 | 0.93 | BID (0.59) | BIDMCL1BCL2L1BAK1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782619-B1 | USE OF GINKGO BILOBA TERPENE LACTONE IN PREPARATION OF DRUGS FOR PREVENTION AND/OR TREATMENT OF TREMORS AND HEALTHCARE PRODUCTS | CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN) | 2026-02-25 | — | — | EP | claimed |
| CN-119970902-A | High-efficiency analgesic pharmaceutical composition, preparation method and application thereof | 传誉归心(北京)药业有限责任公司 | 2025-05-13 | — | — | CN | claimed |
| CN-117159535-A | Composition, medicine and health product for preventing and/or treating tremors | 成都百裕制药股份有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-110522748-B | Application of ginkgolide in preparing medicament and health-care product for preventing and/or treating tremors | 成都百裕制药股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-111803487-B | Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome | 成都百裕制药股份有限公司 | 2022-12-02 | — | — | CN | claimed |
| CN-113332318-B | Pharmaceutical composition with effect of improving depression symptoms and preparation method thereof | 四川省食用菌研究所 | 2022-11-29 | — | — | CN | claimed |
| CN-110433157-B | Application of ginkgolide in preparation of medicine for preventing and/or treating vertigo | 成都百裕制药股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| US-20220193030-A1 | USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRE-STROHL SYNDROME | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2022-06-23 | — | — | US | claimed |
| CN-114395267-A | Epoxy asphalt and preparation method and application thereof | 中路交建(北京)工程材料技术有限公司 | 2022-04-26 | — | — | CN | claimed |
| EP-3936125-A1 | USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRÉ-STROHL SYNDROME | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-01-12 | — | — | EP | claimed |
| CN-103102348-A | Oxadiazole compound and preparation method thereof, medicine composition and application thereof | UNIV SHANGHAI JIAOTONG | 2013-05-15 | — | — | CN | claimed |
| CN-103102322-A | Oxazole compound and preparation method thereof, medicine composition and application thereof | UNIV SHANGHAI JIAOTONG | 2013-05-15 | — | — | CN | claimed |
| EP-2323968-B1 | INTERNAL DONOR FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORP (US) | 2013-03-27 | — | — | EP | claimed |
| CN-102898402-A | Benzisoselenazolone-modified pyrrolyl formate-substituted indolone compound and use thereof | UNIV BEIJING | 2013-01-30 | — | — | CN | claimed |
| EP-2460539-A1 | NANOSPHERE OR MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF | Xi'an Libang Medical Technology Co., Ltd. (CN) | 2012-06-06 | — | — | EP | claimed |
| US-20120121711-A1 | MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF | XI'AN LIBANG MEDICAL TECHNOLOGY CO., LTD. (CN) | 2012-05-17 | — | — | US | claimed |
| EP-2417975-A1 | FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF | Xi'an Libang Medical Technology Co., Ltd. (CN) | 2012-02-15 | — | — | EP | claimed |
| US-20110318420-A1 | FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF | XI'AN LIBANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2011-12-29 | — | — | US | claimed |
| CN-101366692-A | Stable Exenatide formulation | JIANGSU HAOSEN PHARMACEUTICAL (CN) | 2009-02-18 | — | — | CN | claimed |
| US-20030111649-A1 | Chemiluminescent composition for emitting red light | KIM, YONG-RAI (KR) | 2003-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318420-A1 | FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF | PGR, CYP19A1, GNRHR | BID 3266/4885MCL1 1870/4885BCL2L1 2846/4885 |
| US-20120121711-A1 | MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF | CHMP4B, SLCO2B1, MSN | BID 3881/4885MCL1 1642/4885BCL2L1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.